The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.
December 15, 2024
Article
Machine learning models improve accuracy in detecting MASH with F2-F3 fibrosis, surpassing noninvasive tests in sensitivity, specificity, and predictive value.
December 06, 2024
Video
Schattenberg reviews results from a posthoc analysis of the ENLIVEN study suggesting pegozafermin’s impact on preventing progression to cirrhosis.
December 05, 2024
Article
A new study showed patients with MASLD have fragmented nocturnal sleep with frequent awakenings per night and a session on healthy sleep habits did not improve sleep parameters.
December 05, 2024
Video
Schattenberg explains pegozafermin’s mechanism of action and describes the importance of preventing progression to cirrhotic MASH.
November 27, 2024
Article
Test your knowledge of the AASLD NAFLD Practice Guidance and its clinical application in light of the new MASLD nomenclature.
November 21, 2024
Video
Lawitz explains issues with traditional FXR agonists for MASH treatment and how FXR314 differs, potentially offering a more safe and efficacious option.
November 21, 2024
Article
Loomba reviews safety and efficacy data for the thyroid hormone receptor beta agonist from a phase 2a trial presented at AASLD The Liver Meeting 2024.
November 19, 2024
Video
Barritt reviews real-world data about the use and benefits of GLP-1 RAs in patients with MASLD.
November 18, 2024
Article
Compared with non-Hispanic White patients, racial/ethnic minority patients were more likely to be removed from the waitlist and not receive a transplant.
November 17, 2024
Article
High adherence to the Mediterranean diet was linked to a lower risk of liver-related outcomes as measured by the Liver Risk score.